Farbstein Motti 4
Research Summary
AI-generated summary
Can‑Fite (CANF) CEO/CFO/COO Motti Farbstein Receives Options (24,000)
What happened
- Motti Farbstein, who serves as Can‑Fite BioPharma's CEO, CFO and COO, was granted a derivative award of 24,000 options (reported as acquisition at $0.00) on June 4, 2026. This is an option grant rather than a cash purchase or sale; the exercise price was originally NIS 5.94 (converted to approximately USD $2.04 using the Bank of Israel rate on 06/05/2026).
Key details
- Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (timely within the 2-business-day window).
- Award size: 24,000 options; reported acquisition price: $0.00 (derivative award).
- Exercise price: NIS 5.94 → ≈ USD $2.04 (conversion rate NIS 2.908 = USD 1.00 on 06/05/2026).
- Vesting: 16 equal quarterly installments beginning 09/04/2026 and ending 04/06/2030, contingent on continued service.
- Trustee registration: For certain Israeli tax benefits, securities under Can‑Fite’s option plans must be registered in the name of a trustee (per filing footnote).
- Shares owned after transaction: Not specified in the provided filing excerpt.
Context
- This filing documents an option grant (award). Because no exercise or sale occurred, it does not represent an immediate cash outlay or liquidity event. Vesting is spread over ~3.5 years, so these options become exercisable gradually subject to continued employment.